BioCryst (BCRX) AI Stock Analysis

• Market Cap: $1.51B
• Dividend Yield: N/A
• Average Volume (3M): 6.33M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: 45.38%
• EPS Growth: 92.85%
• Country: US
• Employees: 580
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.06
• Shares Outstanding: 210,543,230
• 10 Day Avg. Volume: 5,806,486
• 30 Day Avg. Volume: 6,334,831
• PEG Ratio: 0.28
• Price to Book (P/B): -3.27
• Price to Sales (P/S): 3.45
• P/FCF Ratio: -29.25
• Enterprise Value/Market Cap: 1.42
• Enterprise Value/Revenue: 3.57
• Enterprise Value/Gross Profit: 3.66
• Enterprise Value/Ebitda: 25.60
• 1Y Price Target: $19.27
• Price Target Upside: 174.11% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): 0.09
• Revenue Forecast (FY): $625.92M

• Rating: 46 Neutral
• Price Target: $6.50 ▼(-7.54% Downside)

BioCryst's overall stock score is primarily influenced by its financial performance challenges, including high leverage and cash flow issues. While the earnings call provided positive insights into revenue growth and strategic initiatives, the technical analysis and valuation metrics indicate bearish sentiment and limited immediate return potential.

Positive Factors

Revenue Growth

Strong revenue growth from ORLADEYO indicates robust market demand and successful product adoption, supporting long-term revenue stability.

Pipeline Expansion

Acquiring Astria enhances BioCryst's pipeline, potentially increasing future revenue streams and strengthening its position in rare disease treatment.

Financial Position Enhancement

Improved financial position through strategic debt reduction and asset sales enhances long-term financial flexibility and reduces risk.

Negative Factors

High Leverage

High leverage poses significant financial risk, potentially limiting the company's ability to invest in growth and manage economic downturns.

Cash Flow Challenges

Negative cash flow growth indicates difficulties in sustaining operations and funding future projects, impacting long-term viability.

Enrollment Delays

Delays in clinical program enrollment can hinder timely product development and market entry, affecting future revenue growth.

BioCryst Business Overview & Revenue Model

Company Description

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, particularly those related to genetic disorders and viral infections. The company's core products include Orladeyo (berotralstat), an oral medication approved for the prevention of hereditary angioedema attacks, and other pipeline candidates aimed at treating conditions such as COVID-19 and various forms of cancer. BioCryst operates primarily in the pharmaceutical sector, leveraging its proprietary drug development technologies to address unmet medical needs.

How the Company Makes Money

BioCryst generates revenue primarily through the sale of its approved products, such as Orladeyo, which contributes to its direct sales revenue. In addition, the company may earn revenue from licensing agreements and collaborations with other pharmaceutical companies, which can include upfront payments, milestone payments upon achieving certain development or sales targets, and royalties on sales of partnered products. The company's ongoing research and development efforts may also lead to additional revenue opportunities through future product launches and potential government grants or partnerships aimed at bringing innovative therapies to market.

BioCryst Financial Statement Overview

Summary

BioCryst demonstrates strong revenue growth and gross profit margins, but faces challenges with profitability and financial stability. High leverage and negative equity are significant concerns, while cash flow improvements are a positive sign. The company needs to address profitability and leverage to enhance financial health.

Income Statement

BioCryst shows a strong gross profit margin of 97% in the TTM, indicating effective cost management. However, the net profit margin is negative, reflecting ongoing losses. Revenue growth is positive at 10.73% TTM, but the company struggles with profitability as evidenced by negative EBIT and EBITDA margins in previous years.

Balance Sheet

The balance sheet reveals high leverage with a negative equity position, as indicated by a debt-to-equity ratio of -1.75 in the TTM. This poses a significant risk. Return on equity is positive, but this is due to negative equity, which distorts the metric. The equity ratio is negative, highlighting financial instability.

Cash Flow

Cash flow analysis shows improvement with a positive operating cash flow in the TTM. However, free cash flow growth is negative, and the operating cash flow to net income ratio is low, indicating challenges in converting income into cash. The free cash flow to net income ratio is relatively high, suggesting some efficiency in cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	599.82M	450.71M	331.41M	270.83M	157.17M	17.81M
Gross Profit	584.13M	438.44M	325.10M	262.80M	149.13M	16.14M
EBITDA	83.54M	12.81M	-116.33M	-143.85M	-121.74M	-167.56M
Net Income	-8.78M	-88.88M	-226.54M	-247.12M	-184.06M	-182.81M
Balance Sheet
Total Assets	446.42M	490.42M	516.96M	550.00M	588.15M	334.71M
Cash, Cash Equivalents and Short-Term Investments	212.87M	320.85M	388.99M	424.31M	507.60M	300.37M
Total Debt	11.95M	841.42M	848.71M	741.45M	593.24M	279.50M
Total Liabilities	834.31M	966.35M	972.49M	844.60M	695.14M	353.98M
Stockholders Equity	-387.89M	-475.93M	-455.53M	-294.60M	-106.99M	-19.26M
Cash Flow
Free Cash Flow	-5.89M	-53.14M	-97.31M	-163.20M	-144.54M	-137.73M
Operating Cash Flow	-5.21M	-52.02M	-95.14M	-161.85M	-142.16M	-137.22M
Investing Cash Flow	87.59M	52.59M	-131.50M	-128.24M	15.80M	-6.86M
Financing Cash Flow	-135.99M	-5.76M	32.48M	88.03M	359.67M	300.59M

BioCryst Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCRX, the sentiment is Negative. The current price of 7.03 is above the 20-day moving average (MA) of 7.02, below the 50-day MA of 7.47, and below the 200-day MA of 8.43, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 46.16 is Neutral, neither overbought nor oversold. The STOCH value of 49.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCRX.

BioCryst Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	79 Outperform	$1.88B	25.75	20.65%	―	20.62%	―
VCEL	71 Outperform	$1.83B	290.70	2.59%	―	16.13%	670.90%
CDTX	55 Neutral	$2.55B	―	-37.05%	―	-100.00%	55.31%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BCRX	46 Neutral	$1.51B	-148.63	―	―	45.38%	92.85%
SRPT	45 Neutral	$1.58B	―	-21.37%	―	47.15%	-311.26%
CLDX	38 Underperform	$1.58B	―	-27.17%	―	-30.25%	-9.70%

BioCryst Corporate Events

BioCryst Pharmaceuticals Shines in Q3 Earnings Call

BioCryst Pharmaceuticals’ recent earnings call conveyed a strong performance marked by notable revenue growth, strategic financial decisions, and promising developments in their pipeline. Despite facing some challenges such as enrollment delays and increased costs, the overall sentiment was positive, indicating a promising outlook for the company.

BioCryst Pharmaceuticals Reports Strong Q3 2025 Results

BioCryst Pharmaceuticals is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases, with its flagship product being ORLADEYO, the first oral, once-daily plasma kallikrein inhibitor.

BioCryst Reports Q3 2025 Financial Growth and Strategy

In the third quarter of 2025, BioCryst Pharmaceuticals reported significant financial growth, with ORLADEYO net revenue reaching $159.1 million, a 37% increase year-over-year. The company completed the sale of its European ORLADEYO business, using proceeds to retire Pharmakon term debt, and announced a definitive agreement to acquire Astria Therapeutics, expected to close in the first quarter of 2026. These strategic moves are expected to enhance BioCryst’s market position and financial stability, with the company raising its full-year revenue guidance and lowering its operating expense outlook for 2025.

The most recent analyst rating on (BCRX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.

BioCryst Announces Merger with Astria Therapeutics

On October 14, 2025, BioCryst Pharmaceuticals announced a merger agreement with Astria Therapeutics, which will see Astria become a wholly owned subsidiary of BioCryst. The merger, expected to close in the first quarter of 2026, involves an exchange of shares and cash, with Astria’s stock to be delisted from Nasdaq. The merger aims to enhance BioCryst’s market position and operational capabilities, with financing commitments secured from Blackstone to support the transaction. The merger agreement includes various conditions and provisions, such as stockholder approval and regulatory clearances, with potential termination fees if the agreement is not fulfilled.

The most recent analyst rating on (BCRX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.

BioCryst Sells European ORLADEYO Business for $250M

On October 1, 2025, BioCryst Pharmaceuticals completed the sale of its European ORLADEYO business to Neopharmed Gentili for $250 million, with potential future milestones of up to $14 million. This transaction allows BioCryst to focus on its U.S. operations, improve its operating margin, and retire a significant portion of its debt, positioning the company for future strategic activities. Neopharmed Gentili will handle the commercialization of ORLADEYO in Europe, ensuring continuity for the brand and patients.

The most recent analyst rating on (BCRX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.

BioCryst’s Chief R&D Officer Resigns Amid CEO Decision

On August 6, 2025, Dr. Helen Thackray announced her resignation as Chief Research and Development Officer of BioCryst Pharmaceuticals, effective September 1, 2025, after not being selected as the next CEO. The company has entered into a Separation Agreement with Dr. Thackray, offering various benefits, and a Consulting Agreement for transition services until the end of 2025, ensuring a smooth transition and continuity in operations.

The most recent analyst rating on (BCRX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.

BioCryst’s BCX17725: A Promising Step Forward in Treating Netherton Syndrome

BioCryst Pharmaceuticals is conducting a Phase 1/1b clinical study titled ‘A Phase 1/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of BCX17725 in Healthy Participants and Multiple Doses of BCX17725 in Participants With Netherton Syndrome.’ The study aims to assess the safety and effectiveness of BCX17725, a new drug, in both healthy individuals and those with Netherton Syndrome, a rare genetic disorder. This study is significant as it explores a potential new treatment option for this condition.

BioCryst’s Earnings Call Highlights Strong Growth and Strategic Moves

BioCryst Pharmaceuticals’ recent earnings call conveyed a positive sentiment, underscoring the company’s strong financial performance and strategic leadership changes. Despite facing challenges such as the sale of its European business and regulatory delays, the overall outlook remains optimistic due to robust execution and advancements in its pipeline.

BioCryst Pharmaceuticals Reports Record Q2 2025 Results

BioCryst Pharmaceuticals, a biotechnology company, focuses on developing oral small-molecule and protein therapeutics for rare diseases, with a flagship product, ORLADEYO, for hereditary angioedema (HAE).